Patent ID: 8183234
Filing Date: 2012-05-22
Classification: A61P,C07D

Abstract:
1. A method for the treatment of disorders associated with abnormal sodium proton exchange activity in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound of the formula 1; or a tautomer, a stereoisomer or a pharmaceutically acceptable salt thereof; wherein, R1 is selected from: hydrogen, halogen, —(C R2 is selected from: hydrogen, halogen, hydroxy, hydroxyalkyl, formyl, alkoxy, (C R3 is selected from hydrogen and halogen; R4 is selected from hydrogen, halogen, —(C R5 is —(C R6 is selected from hydrogen, halogen, (C R7 is guanidino or guanidino carbonyl; R8 is hydrogen; R′ and R″ are independently from each other selected from: hydrogen, alkyl, (C R′″ is selected from: heterocyclyl, (C where alkyl is (C where aryl is (C where heteroaryl is a 5 or 6 membered ring system containing one, two or three ring atoms selected from N, O and S, which is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, nitro, amino, alkylamino, alkyl, alkoxy and alkylcarbonyl; where heterocyclyl is a 5 or 6 membered ring system containing one, two or three ring atoms selected from N, O and S, which is unsubstituted or substituted by one or two of the same or different groups selected from: alkyl, (C U is C(O), CR V is CR W is S(O) wherein, R R and wherein the disorders associated with abnormal sodium-proton exchange activity are selected from: ischemia or reperfusion induced tissue damage as occurring in (i) cardiovascular diseases selected from the group consisting of angina pectoris, acute coronary syndrome, myocardial infarction, myocardial stunning, arrhythmias, cardiac dysfunction, post-infarct remodeling, hypertension and vascular restenosis, (ii) cardiovascular surgical procedures selected from the group consisting of coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA) or percutaneous transluminal coronary intervention (PTCI), organ transplantation, and (iii) cerebrovascular disorders selected from the group consisting of cerebral ischemic stroke and edema; and thrombosis.